Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Neovascular Age-Related Macular Degeneration

Drug Information

Target Indication

Neovascular Age-Related Macular Degeneration

Clinical Trial

Last updated: 12/16/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Related Pipeline

Acute Coronary Syndrome

Overactive Bladder

Pneumonia, Bacterial

Chronic Kidney Disease

Colorectal Neoplasms